A dialysis turnaround with a 2026 test
- FMS is the world leader in kidney dialysis products and services, based on publicly reported revenue.
- The turnaround is real so far: Value-Based Care was profitable for a second straight quarter in Q1 2026.
- The 5008X rollout is the main product story, with about 100 clinics converted by early April 2026.
- The hard part is still ahead, since TDAPA support fades in the second half of 2026.
- ACA subsidy changes could create a EUR 50 million headwind as patient grace periods end.
Turnaround, then proof
The bull case is simple. Fresenius Medical Care is cutting costs, closing weak clinics, and getting its risk-based care business into the black. Value-Based Care was profitable for the second quarter in a row in Q1 2026. The FME25+ program also produced faster savings, helped by 64 U.S. clinic exits in Q1.
The new 5008X CAREsystem is the biggest product catalyst. Management says it passed 100,000 treatments on the system in the first week of April 2026, with around 100 clinics converted. The 2026 goal is to replace about 20% of the U.S. installed base in company clinics and transition about 36,000 patients across 28 states.
The bear case is that 2026 is still a bridge year. First-half earnings get help from TDAPA, a temporary Medicare add-on payment for certain dialysis drugs. That benefit turns into a steep headwind in the second half as the support phases down.
The open question is volume. U.S. same-market treatment growth is expected to be flat in 2026. To change that, FMS needs fewer missed treatments, lower mortality, and no big loss of insured patients as ACA subsidy limits start to bite.
Clinics plus the tools
FMS is vertically integrated. That means it treats patients in its own dialysis clinics, manages some patients under risk-based contracts, and also makes the machines and supplies used in dialysis.
Care Delivery is the clinic business. It earns money when patients receive dialysis treatments, but it is exposed to wage inflation, staffing shortages, missed treatments, and changes in reimbursement from Medicare, Medicaid, Medicare Advantage, and commercial insurers.
Care Enablement is the product business. It sells hemodialysis machines, peritoneal dialysis cyclers, dialyzers, bloodlines, solutions, concentrates, renal drugs, water treatment systems, and other products. It also supplies the company's own clinics, so reported segment revenue includes sales that are later eliminated at the group level.
Value-Based Care manages patients under contracts where FMS can share in savings if care is better and cheaper, but can also lose money if medical costs run too high. This segment reached operating income for full-year 2025 and stayed profitable in Q1 2026, which is a key part of the turnaround.
Dialysis at scale
Dialysis clinics
The clinic network is the core business. It treated patients through thousands of sites, but FMS is pruning the base by closing or selling weaker locations.
5008X CAREsystem
The 5008X is the main U.S. upgrade cycle. FMS targets replacing about 20% of its U.S. installed base in 2026 and the full Fresenius Kidney Care base by the end of 2030.
Hemodialysis machines and dialyzers
These are the core tools for in-center dialysis. Care Enablement saw volume growth and positive pricing outside China, but China procurement rules are a drag.
Peritoneal dialysis cyclers and supplies
These products support home-based dialysis. FMS is also expanding digital tools such as kinexus PD remote therapy management.
Value-Based Care contracts
This is a care-management business, not a device line. It can add profit if FMS lowers total medical costs for kidney patients while meeting quality goals.
Renal pharmaceuticals and related products
FMS benefits when reimbursement supports dialysis drugs and add-on products. The near-term issue is the phase-out of TDAPA support for phosphate binders.
Three pieces, one kidney focus
Segment mix uses fiscal 2025 segment revenue before inter-segment eliminations from the 2025 Form 20-F. Care Delivery is still the largest piece, while Value-Based Care is smaller but growing faster.
What could break
ACA coverage drop-off
High impact · Medium oddsThe OBBBA limits ACA premium tax credit availability. Management saw little Q1 2026 impact, but still expects affordability pressure to create about a EUR 50 million headwind from Q2 onward. If patients lose coverage or delay care, FMS can lose treatments and face a worse payor mix.
TDAPA cliff in H2 2026
High impact · High oddsTDAPA is a temporary Medicare add-on payment for certain dialysis drugs. It helps first-half 2026 earnings, but the phase-out creates a steep second-half headwind. This makes early 2026 profit look cleaner than the full-year run rate may be.
Flat U.S. treatment growth
High impact · Medium oddsFMS needs patients to show up for dialysis several times a week. Flu seasons, mortality, labor gaps, and missed treatments can keep volumes flat. Management expects flat U.S. same-market treatment growth for 2026, so there is not much room for another demand setback.
China procurement pressure
Medium impact · High oddsChina's volume-based procurement rules push down prices for some healthcare products. FMS expects about a EUR 50 million impact in 2026 from China procurement and related policies. This can offset better product volume and pricing elsewhere.
Cost inflation and labor shortages
Medium impact · High oddsDialysis clinics need trained nurses and technicians. Wage inflation, medical benefit costs, and tight clinical labor markets can eat into savings from FME25+. If staffing stays tight, service quality and patient attendance may also suffer.
Third-party cyber failure
Medium impact · Medium oddsFMS depends on outside service providers for parts of its operations. A cyberattack at a vendor could disrupt billing, patient data, or clinic workflows. The risk matters because dialysis is time-sensitive care.
In one breath
What does Fresenius Medical Care do?
FMS treats people with kidney failure through dialysis clinics. It also makes dialysis machines, dialyzers, peritoneal dialysis products, renal drugs, and related healthcare products.
Why does the 5008X matter?
The 5008X is the company's new hemodiafiltration-capable dialysis system for the U.S. FMS wants it to reduce missed treatments and improve outcomes, and it plans to replace the full Fresenius Kidney Care installed base by the end of 2030.
What is Value-Based Care at FMS?
Value-Based Care means FMS manages groups of kidney patients under contracts tied to total medical cost and quality. It can earn more if care is better and cheaper, but it can lose money if medical costs run above expectations.
What is the main 2026 risk for FMS?
The main risk is that earnings weaken in the second half as TDAPA support fades and ACA subsidy limits start to affect patient coverage. Flat U.S. treatment growth gives FMS less room to absorb those shocks.